Prof. Dr. Georg Schett is a distinguished professor of Internal Medicine and the head of the Department of Medicine 3—Rheumatology and Immunology—at Friedrich-Alexander University Erlangen-Nürnberg in Germany. Since 2006, he has been at the forefront of research on rheumatoid arthritis and cell therapy for autoimmune diseases, solidifying his reputation as one of the world’s foremost experts in the field. His work encompasses basic, translational, and clinical research, focusing on the molecular and cellular mechanisms underlying rheumatic conditions.

Dr. Schett’s leadership is exemplified through several high-profile research initiatives, including the priority program IMMUNOBONE, the DFG CRC1181 “Checkpoints for Resolution of Inflammation,” and the METARTHROS project, which investigates the relationship between metabolism and arthritis. His groundbreaking findings, particularly the transformative nature of anti-CD19 CAR T-cell therapy for refractory systemic lupus reported in 2022, have made significant contributions to the understanding and treatment of autoimmune diseases.

With over 820 peer-reviewed publications and invitations to more than 660 congresses and conferences, Dr. Schett is a prominent figure in rheumatology. He has received numerous accolades, including the Dr. Franciscus Blondel Medal and the Carol-Nachman Prize, and was honored with the 2023 Gottfried Wilhelm Leibniz Prize. As a member of the Leopoldina National Academy of Sciences of Germany, he actively participates in shaping the future of research in rheumatology.

Dr. Schett earned his medical degree from the University of Innsbruck, Austria, and completed his specialty training in internal medicine and rheumatology at the University of Vienna. His ongoing commitment to advancing the field through research, education, and international collaboration continues to impact patients and the scientific community alike.